JP2021512904A5 - - Google Patents
Info
- Publication number
- JP2021512904A5 JP2021512904A5 JP2020542613A JP2020542613A JP2021512904A5 JP 2021512904 A5 JP2021512904 A5 JP 2021512904A5 JP 2020542613 A JP2020542613 A JP 2020542613A JP 2020542613 A JP2020542613 A JP 2020542613A JP 2021512904 A5 JP2021512904 A5 JP 2021512904A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical composition
- composition according
- patient
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627408P | 2018-02-07 | 2018-02-07 | |
| US62/627,408 | 2018-02-07 | ||
| US201862694318P | 2018-07-05 | 2018-07-05 | |
| US62/694,318 | 2018-07-05 | ||
| US201862772956P | 2018-11-29 | 2018-11-29 | |
| US62/772,956 | 2018-11-29 | ||
| PCT/US2019/016844 WO2019157050A1 (en) | 2018-02-07 | 2019-02-06 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512904A JP2021512904A (ja) | 2021-05-20 |
| JP2021512904A5 true JP2021512904A5 (enExample) | 2022-02-16 |
Family
ID=67540670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542613A Pending JP2021512904A (ja) | 2018-02-07 | 2019-02-06 | Ａｎｃａ関連血管炎の治療のためのある種の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニル］−１，４−オキサゼパン−２−カルボキサミド |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20190247400A1 (enExample) |
| EP (1) | EP3749326A4 (enExample) |
| JP (1) | JP2021512904A (enExample) |
| KR (1) | KR20200118103A (enExample) |
| AU (1) | AU2019217870A1 (enExample) |
| CA (1) | CA3089240A1 (enExample) |
| WO (1) | WO2019157050A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| PT3758708T (pt) | 2018-03-01 | 2025-02-13 | Astrazeneca Ab | Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida |
| WO2020018551A1 (en) * | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| AU2021314104A1 (en) | 2020-07-20 | 2023-01-19 | Insmed, Inc. | Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions |
| PL4129989T3 (pl) * | 2020-08-26 | 2025-02-24 | Haisco Pharmaceuticals Pte. Ltd. | Pochodna nitrilu działająca jako inhibitor dipeptydylopeptydazy 1 i jej zastosowanie |
| WO2022166721A1 (zh) * | 2021-02-05 | 2022-08-11 | 南京明德新药研发有限公司 | 含1，4-氧杂氮杂环庚烷的并环类衍生物 |
| US20250101011A1 (en) * | 2022-01-11 | 2025-03-27 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd | Peptidyl nitrile compound and use thereof |
| JP2025508359A (ja) * | 2022-02-16 | 2025-03-26 | インスメッド インコーポレイテッド | 化膿性汗腺炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド |
| WO2023243601A1 (ja) | 2022-06-13 | 2023-12-21 | モジュラス株式会社 | アザシクロアルキルカルボニル環状アミン化合物 |
| JP2026503035A (ja) | 2023-01-06 | 2026-01-27 | インスメッド インコーポレイテッド | 新規な可逆性ｄｐｐ１阻害剤及びその用途 |
| CN120693326A (zh) * | 2023-02-15 | 2025-09-23 | 英斯梅德股份有限公司 | 某些1，4-氧杂氮杂环庚烷-2-甲酰胺作为dpp1抑制剂的用途 |
| WO2025162472A1 (en) | 2024-01-31 | 2025-08-07 | Insmed Incorporated | Linear dipeptidyl peptidase 1 inhibitors and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101087807A (zh) * | 2004-10-05 | 2007-12-12 | 健泰科生物技术公司 | 治疗血管炎的方法 |
| JP6479476B2 (ja) * | 2012-02-21 | 2019-03-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ＳｙｋチロシンキナーゼインヒビターおよびＧＣＮ２セリンキナーゼインヒビターとしての８−置換２−アミノー［１，２，４］トリアゾロ［１，５−Ａ］ピラジン類 |
| WO2014091443A1 (en) * | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
| JP6437929B2 (ja) * | 2013-03-14 | 2018-12-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
| NO2699580T3 (enExample) * | 2014-01-24 | 2018-02-24 | ||
| WO2016016242A1 (en) * | 2014-08-01 | 2016-02-04 | Boehringer Ingelheim International Gmbh | Substituted oxetanes and their use as inhibitors of cathepsin c |
| HUE047208T2 (hu) * | 2014-09-12 | 2020-04-28 | Boehringer Ingelheim Int | A katepszin-C spirociklikus inhibitorai |
| WO2018022978A1 (en) * | 2016-07-29 | 2018-02-01 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis |
-
2019
- 2019-02-06 EP EP19751012.6A patent/EP3749326A4/en not_active Withdrawn
- 2019-02-06 US US16/269,191 patent/US20190247400A1/en not_active Abandoned
- 2019-02-06 CA CA3089240A patent/CA3089240A1/en active Pending
- 2019-02-06 JP JP2020542613A patent/JP2021512904A/ja active Pending
- 2019-02-06 US US16/968,381 patent/US20200390781A1/en not_active Abandoned
- 2019-02-06 AU AU2019217870A patent/AU2019217870A1/en not_active Abandoned
- 2019-02-06 WO PCT/US2019/016844 patent/WO2019157050A1/en not_active Ceased
- 2019-02-06 KR KR1020207025220A patent/KR20200118103A/ko not_active Withdrawn
-
2021
- 2021-01-25 US US17/157,216 patent/US20210186984A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022096662A5 (enExample) | ||
| JP2023156479A5 (enExample) | ||
| JP2021530513A5 (enExample) | ||
| JP5749802B2 (ja) | 非定型抗精神病薬及びｔａａｒ１アゴニストを含む組合せ | |
| JP2021530525A5 (enExample) | ||
| JP2021515006A5 (enExample) | ||
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| CN1155409C (zh) | 用于预防和治疗动脉硬化的药物组合物 | |
| JP2022191257A5 (enExample) | ||
| RU2000114635A (ru) | Бензотиазольные ингибиторы протеинтирозинкиназ | |
| BR112021003467A2 (pt) | composições de inibidores de cxcr4 e métodos de preparação e uso | |
| SK112001A3 (en) | Agents with an antidepressive effect containing pramipexol and an additional antidepressant drug | |
| WO2002005797A2 (en) | Use of dopamine d2/d3 receptor agonists to treat fibromyalgia | |
| EP3749326A1 (en) | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides | |
| JP2024516826A5 (enExample) | ||
| RU2010117178A (ru) | Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний | |
| WO2020018547A1 (en) | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis | |
| JP2022554276A5 (enExample) | ||
| WO2019046287A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | |
| WO2023049886A1 (en) | Imidazopyridazine il-17 inhibitor compounds | |
| WO2019151470A1 (ja) | 眼内血管新生及び／又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬 | |
| JP2022519274A5 (enExample) | ||
| JP2021519285A5 (enExample) | ||
| CN1233178A (zh) | 用于治疗性功能障碍的吡唑啉酮类 | |
| US20020147206A1 (en) | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy |